Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors

Journal of Controlled Release

Volumn 158, Issue 3, 2012, Pages 386-392

  Bajaj, Gaurav ^a   Kim, Mi Ran ^b   Mohammed, Sulma I ^b   Yeo, Yoon ^a,b,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Drug delivery; Hydrogel; Intraperitoneal; Paclitaxel; Particles

Indexed keywords

ANTITUMOR EFFECT; CROSS-LINKABLE; DRUG CONCENTRATION; HYALURONIC ACIDS; IN-SITU; IN-VITRO; INTRAPERITONEAL; NUDE MICE; OVARIAN CANCERS; PACLITAXEL; PERITONEAL CAVITY; RELEASE KINETICS; TEMPORAL AVAILABILITY; THERAPEUTIC EFFECTS;

CHEMOTHERAPY; DRUG DELIVERY; ELEMENTARY PARTICLES; ORGANIC ACIDS; TUMORS;

HYDROGELS;

HYALURONIC ACID; HYALURONIDASE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CANCER; PERITONEAL FLUID; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; HYALURONIC ACID; HYDROGELS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862777576     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.001     Document Type: Article

References (56)

1. American Cancer Society, Cancer Facts & Figures 2010 http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf 2010
2. A.A. Poveda, R.R. Salazar, J.J.M. del Campo, C.C. Mendiola, J.J. Cassinello, B.B. Ojeda, J.J.A. Arranz, A.A. Oaknin, J.J. García- Foncillas, M.M.J. Rubio, and A.A. González Martín Update in the management of ovarian and cervical carcinoma Clin. Transl. Oncol. 9 7 2007 443 451
3. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, J.A. Young, E.W. Franklin, D.L. Clarke-Pearson, V.K. Malviya, and B. DuBeshter Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 26 1996 1950 1955 (Pubitemid 26428219)
4. G. Bajaj, and Y. Yeo Drug delivery systems for intraperitoneal therapy Pharm. Res. 27 5 2010 735 738
5. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, L.J. Copeland, J.L. Walker, and R.A. Burger Intraperitoneal cisplatin and paclitaxel in ovarian cancer N. Engl. J. Med. 354 1 2006 34 43 (Pubitemid 43048949)
6. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, R.S. Mannel, K. DeGeest, E.M. Hartenbach, and R. Baergen Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 17 2003 3194 3200 (Pubitemid 46606249)
7. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J. Clin. 61 3 2011 183 203
8. R.L. Dedrick, C.E. Myers, P.M. Bungay, and V.T. DeVita Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat. Rep. 62 1 1978 1 11 (Pubitemid 8278518)
9. M. Markman Intraperitoneal drug delivery of antineoplastics Drugs 61 8 2001 1057 1065 (Pubitemid 32663868)
10. N. Aviram, S. Alexander, G. Alfredo, E. Jesus, and P. Pompiliu Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future J. Surg. Oncol. 100 4 2009 335 344
11. NCI NCI Clinical Announcement on Intraperitoneal Therapy for Ovarian Cancer http://ctep.cancer.gov/highlights/docs/clin-annc-010506.pdf 2006
12. E.A. Ho, P.L. Soo, C. Allen, and M. Piquette-Miller Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors J. Control. Release 117 1 2007 20 27 (Pubitemid 46161865)
13. P. Zahedi, R. De Souza, L. Huynh, M. Piquette-Miller, and C. Allen Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer Mol. Pharmaceutics 8 1 2011 260 269
14. F. Mohamed, P. Marchettini, O.A. Stuart, and P.H. Sugarbaker Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions Cancer Chemother. Pharmacol. 52 5 2003 405 410 (Pubitemid 37363614)
15. F. Mohamed, O.A. Stuart, and P.H. Sugarbaker Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions J. Surg. Res. 113 1 2003 114 120 (Pubitemid 36999800)
16. M. Tsai, Z. Lu, J. Wang, T.-K. Yeh, M. Wientjes, and J. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm. Res. 24 9 2007 1691 1701 (Pubitemid 47206619)
17. R.F. Ozols Challenges for chemotherapy in ovarian cancer Ann. Oncol. 17 Suppl. 5 2006 v181 v187
18. M. Markman, and J.L. Walker Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment J. Clin. Oncol. 24 6 2006 988 994 (Pubitemid 46638854)
19. H. Lu, B. Li, Y. Kang, W. Jiang, Q. Huang, Q. Chen, L. Li, and C. Xu Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting Cancer Chemother. Pharmacol. 59 2 2007 175 181 (Pubitemid 44885147)
20. Y. Yeo, T. Ito, E. Bellas, C.B. Highley, R. Marini, and D.S. Kohane In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions Ann. Surg. 245 5 2007 819 824 (Pubitemid 46684114)
21. H. Gelderblom, J. Verweij, D.e.M. van Zomeren, D. Buijs, L. Ouwens, K. Nooter, G. Stoter, and A. Sparreboom Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel Clin. Cancer Res. 8 4 2002 1237 1241 (Pubitemid 35177380)
22. D.S. Kohane, J.Y. Tse, Y. Yeo, R. Padera, M. Shubina, and R. Langer Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum J. Biomed. Mater. Res. A 77 2 2006 351 361 (Pubitemid 47233537)
23. Z. Lu, M. Tsai, D. Lu, J. Wang, M.G. Wientjes, and J.L.S. Au Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer J. Pharmacol. Exp. Ther. 327 3 2008 673 682
24. T. Tamura, J. Imai, A. Matsumoto, M. Tanimoto, A. Suzuki, Y. Horikiri, T. Suzuki, H. Yoshino, and O. Ike Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres Eur. J. Pharm. Biopharm. 54 1 2002 1 7 (Pubitemid 34663850)
25. S. Dadashzadeh, N. Mirahmadi, M.H. Babaei, and A.M. Vali Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge J. Control. Release 148 2010 177 186
26. Y. Yeo, and D.S. Kohane Polymers in the prevention of peritoneal adhesions Eur. J. Pharm. Biopharm. 68 1 2008 57 66 (Pubitemid 350186238)
27. E.A. Ho, V. Vassileva, C. Allen, and M. Piquette-Miller In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel J. Control. Release 104 1 2005 181 191 (Pubitemid 40615245)
28. P.L. Soo, J. Cho, J. Grant, E. Ho, M. Piquette-Miller, and C. Allen Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology Eur. J. Pharm. Biopharm. 69 1 2008 149 157
29. V. Vassileva, J. Grant, R. De Souza, C. Allen, and M. Piquette-Miller Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Cancer Chemother. Pharmacol. 60 6 2007 907 914 (Pubitemid 47389398)
30. K. Hyoudou, M. Nishikawa, M. Ikemura, Y. Kobayashi, A. Mendelsohn, N. Miyazaki, Y. Tabata, F. Yamashita, and M. Hashida Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells J. Control. Release 122 2007 151 158 (Pubitemid 47361405)
31. R. De Souza, P. Zahedi, C.J. Allen, and M. Piquette-Miller Biocompatibility of injectable chitosan-phospholipid implant systems Biomaterials 30 23-24 2009 3818 3824
32. P. Zahedi, R. De Souza, M. Piquette-Miller, and C. Allen Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity Int. J. Pharm. 377 1-2 2009 76 84
33. J. Yu, H.J. Lee, K. Hur, M.K. Kwak, T.S. Han, W.H. Kim, S.C. Song, K. Yanagihara, H.K. Yang, The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model, Invest. New Drugs (in press), doi: 10.1007/s10637-010-9499-y.
34. Y. Wang, C. Gong, L. Yang, Q. Wu, S. Shi, H. Shi, Z. Qian, and Y. Wei 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice BMC Cancer 10 2010 402
35. Y. Yeo, M. Adil, E. Bellas, A. Astashkina, N. Chaudhary, and D.S. Kohane Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide J. Control. Release 120 3 2007 178 185 (Pubitemid 47064479)
36. A. Sparreboom, L. van Zuylen, E. Brouwer, W.J. Loos, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res. 59 7 1999 1454 1457 (Pubitemid 29160110)
37. P. Bulpitt, and D. Aeschlimann New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels J. Biomed. Mater. Res. 47 2 1999 152 169 (Pubitemid 29409734)
38. M. Satpathy, L. Cao, R. Pincheira, R. Emerson, R. Bigsby, H. Nakshatri, and D. Matei Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase Cancer Res. 67 15 2007 7194 7202 (Pubitemid 47206547)
39. P.X. Bouckaert, J.L. Evers, W.H. Doesburg, L.A. Schellekens, P.H. Brombacher, and R. Rolland Patterns of changes in proteins in the peritoneal fluid of women during the periovulatory phase of the menstrual cycle J. Reprod. Fertil. 77 2 1986 329 336 (Pubitemid 16075388)
40. Y. Yeo, E. Bellas, C.B. Highley, R. Langer, and D.S. Kohane Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated injury model Biomaterials 28 25 2007 3704 3713 (Pubitemid 46863374)
41. F. Hartveit, and S. Thunold Peritoneal fluid volume and the oestrus cycle in mice Nature 210 5041 1966 1123 1125
42. E. Auzenne, S.C. Ghosh, M. Khodadadian, B. Rivera, D. Farquhar, R.E. Price, M. Ravoori, V. Kundra, R.S. Freedman, and J. Klostergaard Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts Neoplasia 9 6 2007 479 486 (Pubitemid 46983450)
43. J.C. Hall, K.A. Heel, J.M. Papadimitriou, and C. Platell The pathobiology of peritonitis Gastroenterology 114 1 1998 185 196 (Pubitemid 28020968)
44. D. Dufrane, M.v. Steenberghe, R.-M. Goebbels, A. Saliez, Y. Guiot, and P. Gianello The influence of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in rats Biomaterials 27 17 2006 3201 3208 (Pubitemid 43344334)
45. Y. Yeo, J.A. Burdick, C.B. Highley, R. Marini, R. Langer, and D.S. Kohane Peritoneal application of chitosan and UV-cross-linkable chitosan J. Biomed. Mater. Res. A 78 4 2006 668 675 (Pubitemid 44300020)
46. Y. Yeo, C.B. Highley, E. Bellas, T. Ito, R. Marini, R. Langer, and D.S. Kohane In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model Biomaterials 27 27 2006 4698 4705 (Pubitemid 43870121)
47. I. Ringel, and S.B. Horwitz Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium J. Pharmacol. Exp. Ther. 242 2 1987 692 698 (Pubitemid 17143505)
48. T.A. Willey, E.J. Bekos, R.C. Gaver, G.F. Duncan, L.K. Tay, J.H. Beijnen, and R.H. Farmen High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma J. Chromatogr. 621 2 1993 231 238
49. G. Lukas, S.D. Brindle, and P. Greengard The route of absorption of intraperitoneally administered compounds J. Pharmacol. Exp. Ther. 178 3 1971 562 566
50. K. Hirano, and C.A. Hunt Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration J. Pharm. Sci. 74 9 1985 915 921 (Pubitemid 15014130)
51. J.E. Kipp The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs Int. J. Pharm. 284 1-2 2004 109 122 (Pubitemid 39349144)
52. G.G. Liversidge, and K.C. Cundy Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs Int. J. Pharm. 125 1 1995 91 97
53. K.F. Roby, F. Niu, R.A. Rajewski, C. Decedue, B. Subramaniam, and P.F. Terranova Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax Adv. Exp. Med. Biol. 622 2008 169 181
54. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, J.R. Baker, D.A. Van Echo, D.D. Von Hoff, and B. Leyland-Jones Hypersensitivity reactions from taxol J. Clin. Oncol. 8 7 1990 1263 1268 (Pubitemid 20195638)
55. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 13 2001 1590 1598 (Pubitemid 32778603)
56. I. De Stefano, A. Battaglia, G. Zannoni, M. Prisco, A. Fattorossi, D. Travaglia, S. Baroni, D. Renier, G. Scambia, C. Ferlini, and D. Gallo Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts Cancer Chemother. Pharmacol. 68 1 2011 107 116